

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-28 (Cancelled).

29. (Currently Amended): A method for treating cancer, the method comprising:

(a) ~~producing activated antigen presenting cells (APC) by primary stimulation *in vitro* that exposes peripheral blood mononuclear cells (PBMC) obtained from a biopsy to anti-CD3 antibodies~~ stimulating peripheral-blood mononuclear cells (PBMC) with immobilized anti-CD3 antibodies to produce primary stimulated PBMC;

(b) ~~obtaining naïve PBMC comprising T cells that are naïve with respect to one or more cancer antigens~~ adding naïve PBMC to the primary stimulated PBMC;

(c) incubating the naïve PBMC in the presence of the ~~activated~~ primary stimulated PBMC to ~~activate the naïve PBMC *in vitro*;~~

(d) ~~expanding subsequently *in vitro* the population of cells (CAPRI cells), derived from the activated naïve PBMC, comprising activated T cells having specificity for the cancer antigens~~ stimulating the naïve PBMC with the primary stimulated PBMC to obtain cascade primed (CAPRI) cells; and

(e) administering the CAPRI cells into a cancer patient,

~~wherein the cancer antigens are presented by the activated APC obtained in step (a) to the PMBC comprising T cells of step (b) in the context of a MHC complex expressed on the surface of the activated APC, and~~

wherein the primary stimulation and/or the activation of naïve PBMC occurs in the presence of at least one cytokine selected from the group of interleukin-2 (IL-2), interleukin-4 (IL-4), and interferon γ (IFN- γ) γ (IFN- γ).

30. (Previously Presented): The method of Claim 29, wherein the cancer is selected from the group consisting of melanoma, breast carcinoma, colorectal carcinoma, ovarian carcinoma, glioblastoma multiform, and bowenoid papilloma.

31. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells intradermally, intravenously, and/or intramuscularly.

32. (Currently Amended): The method of Claim 29, wherein administering the CAPRI cells comprises:

injecting CAPRI cells in a dosage range from ~~about~~ 0.5 to ~~about~~ 30 million cells per injection into the cancer patient.

33. (Currently Amended): The method of Claim 29, wherein administering the CAPRI cells comprises:

administering CAPRI cells into a tumor of the cancer patient, wherein the diameter of the tumor is ~~about~~ less than 0.5 cm ~~or less~~.

34. (Previously Presented): The method of Claim 29, wherein the CAPRI cells are administered in conjunction with radiotherapy.

35. (Previously Presented): The method of Claim 29, wherein administering the CAPRI cells further comprises:

~~Administering CD3-activated~~ administering CD3-activated T cells.

36.- 44. (Cancelled).